TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00976768
Drug: oxaliplatin, 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
Study: NCT02752867
Drug: Jianpi Yishen Huatan Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
Study: NCT01244334
Drug: Prednisolone acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
Study: NCT01270672
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to MDMA or carvedilol
Study: NCT02697955
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg bupivacaine and 50 μg adrenalin
Study: NCT01324583
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT03115489
Drug: Traditional Treatment (Group T)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive traditional drug infusions
Study: NCT01703286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Glimepiride
Study: NCT01703286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Linagliptin
Study: NCT03997539
Drug: Treatment of physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
Study: NCT00958568
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 or 50 mg/day fixed dosing for 27 weeks
Study: NCT01208896
Drug: Reduced_intensity conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
Study: NCT02135471
Drug: acellular dermal matrix graft
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
Study: NCT03108755
Drug: ASP7713
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03108755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01631032
Drug: Qi-tonifying Chinese herbal products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
Study: NCT03320447
Drug: methyl-aminolevulinate application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Study: NCT01234402
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 orally~Twice a day for 14 days
Study: NCT04014387
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcrystalline cellulose) capsules will be used.
Study: NCT00019513
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00019513
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01870700
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
Study: NCT02278276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg capsules containing placebo
Study: NCT00447863
Drug: Levonorgestrel/Ethinyl Estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02717871
Drug: Cefazolin in combination with either tobramycin or gentamicin
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).
Study: NCT02717871
Drug: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
Study: NCT02717871
Drug: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
Study: NCT01204840
Drug: Patch protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped.
Study: NCT00367640
Drug: 100 IR grass pollen allergen extract tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT00367640
Drug: 300 IR grass pollen allergen extract tablet
Normalized name: orchard grass pollen extract 300 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT00367640
Drug: 500 IR grass pollen allergen extract tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT00367640
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT01671488
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
Study: NCT00520819
Drug: Antioxidant-rich food items
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01106534
Drug: placebo + aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Study: NCT00887172
Drug: Jing Fang Bai Du san
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Study: NCT00887172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
Study: NCT00887172
Drug: Ying Qiao san
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Study: NCT02699281
Drug: ultra-micronized palmitoylethanolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultra-micronized palmitoylethanolamide 600 mg twice a day
Study: NCT02699281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: um-PEA like placebo twice a day
Study: NCT04558346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40ug/kg twice daily by self-injection
Study: NCT02391623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
Study: NCT03813563
Drug: RL
Normalized name: Arlex
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactated Ringer's
Study: NCT03719560
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic methotrexate
Study: NCT00428727
Drug: Controlled nitric oxide releasing patch
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily application of nitric oxide patch during 90 days
Study: NCT00428727
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily application during 90 days
Study: NCT02586246
Drug: CDP870
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injection
Study: NCT00003342
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04533841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03042013
Drug: ASP8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03464058
Drug: BOS172767 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT03464058
Drug: BOS172767 liquid capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT03464058
Drug: BOS172767 micronized capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT03464058
Drug: BOS172767 immediate release capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT03464058
Drug: BOS172767 matching placebo capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT03464058
Drug: BOS172767 matching placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01455428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Study: NCT01062451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment daily.
Study: NCT01269541
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Normalized name: clindamycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Study: NCT00555841
Drug: ALC and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALC and Placebo
Study: NCT04497701
Drug: PEG-rhG-CSF group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
Study: NCT04497701
Drug: rhG-CSF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
Study: NCT02200822
Drug: beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02756624
Drug: AC-170 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01154634
Drug: AZD2516, 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral
Study: NCT01154634
Drug: AZD2516, 16 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral
Study: NCT01154634
Drug: AZD2516, 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral
Study: NCT01154634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral
Study: NCT02194621
Drug: Total Flavor option 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
Study: NCT02194621
Drug: Total Flavor option 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
Study: NCT00478972
Drug: placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT01901471
Drug: Single bolus of Placebo of CicloMulsion® (Neurovive).
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes.
Study: NCT01729598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule without active study medication in identical capsules as experimental medicine.
Study: NCT03017703
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01316302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, taken QD for 12 weeks.
Study: NCT02194621
Drug: Placebo toothpaste: Crest Cavity Protection toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
Study: NCT00443430
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
Study: NCT00184912
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04947566
Drug: Comparison of Efficacy of Naproxen versus Ibuprofen
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
Study: NCT00053846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03616769
Drug: antiplatelet drugs ,statins ,antihypertensive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the international guidelines, we treated patients who suffered from different disease.
Study: NCT03837756
Drug: 3BNC117 and 10-1074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Study: NCT03008590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule each evening
Study: NCT00829166
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Study: NCT04338022
Drug: Placebo (match to Evobrutinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo match to Evobrutinib BID in DBTP.
Study: NCT04408092
Drug: Granulocyte Macrophage Colony Stimulation Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
Study: NCT02084134
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg at the time of surgery
Study: NCT04436510
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily
Study: NCT00841295
Drug: Parenteral L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
Study: NCT01328288
Drug: standard ART according to the Thai Ministry of Public Health national guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Study: NCT02332031
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
Study: NCT00659334
Drug: Ferumoxtran-10 (Combidex)
Normalized name: acetaminophen / caffeine / phenyltoloxamine citrate / salicylamide Oral Capsule [Combiflex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 mg/kg
Study: NCT00607646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
Study: NCT04514367
Drug: ANX005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT01879748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)